Search PubMed⌕ Search

Biomedical subjects

O H Gyde

Publications and source records attributed to O H Gyde.

At least 19 recordsLinked to original sources

Placebo-controlled trial of lisinopril in normotensive diabetic patients with incipient nephropathy.

To study the effects of an angiotensin converting enzyme inhibitor, lisinopril, on renal function in incipient diabetic nephropathy, a prospective double-blind randomised placebo-controlled single centre study was set up at our outpatient diabetic-renal clinic. There were 27 patients with Type I and Type II diabetes with an albumin excretion rate of between 20 micrograms/min and 200 micrograms/min, respectively and no hypertension. Intervention treatment with placebo or low dose lisinopril was for 48 weeks. The main outcome changes were in urinary albumin excretion rate, urinary prostaglandin excretion, and glomerular filtration rate. Secondary outcome measures included changes in BP and heart rate. Of the 32 patients entered into the study, 27 completed 48 weeks treatment (12 lisinopril, 15 placebo). Mean (+/- SD) urinary albumin excretion rate fell from 57.6 (25.7) micrograms/min (n = 15) at visit 1 to 26.8 (26.7) micrograms/min (n = 12) at visit 7 after 48 weeks treatment in the lisinopril group but not in the placebo group: 119.2 (116.6) micrograms/min (n = 17) vs. 113.7 (77.0) micrograms/min (n = 15). There was a least squares mean treatment difference of -67.6 micrograms/min (95% confidence interval (CI), -115.0 to -20.2, P < 0.01) in favour of lisinopril compared with placebo. After 48 weeks treatment seven lisinopril treated patients were normoalbuminuric and five were microproteinuric; three placebo treated patients were normoalbuminuric, nine were microalbuminuric and three were macroproteinuric. Excretion of prostaglandin-F1 alpha (PGF1 alpha) and thromboxane-B2 (TXB2) fell in the lisinopril treated group.(ABSTRACT TRUNCATED AT 250 WORDS)

Adolescent↗

Comparison of the effects of an angiotensin converting enzyme inhibitor and a calcium antagonist in hypertensive, macroproteinuric diabetic patients: a randomised double-blind study.

The objective of this study was to compare the effects of an angiotensin converting enzyme inhibitor, lisinopril, with those of a calcium blocker, nifedipine, on BP control and renal function, in a prospective randomised double-blind, double-dummy trial lasting 19 weeks in patients with diabetic nephropathy. We enrolled 28 diabetic patients with hypertension and macroproteinuria from the out-patient diabetic-renal clinic. The antihypertensive treatment consisted of lisinopril or nifedipine, and their effect on arterial BP, urinary albumin excretion, glomerular filtration rate, and renal blood flow were measured. BPs at entry were 166/99 (SD 23/9) mmHg for the lisinopril group and 165/99(21/7) mmHg for the nifedipine group. BPs fell to 143/88 (17/13) mmHg for the lisinopril group and 148/85(25/10) mmHg for the nifedipine group at the end of the study. The albumin excretion rate fell in the lisinopril group from 738.7 (635.2) micrograms/min to 644.6 (965.2) micrograms/min and rose in the nifedipine group from 981.2 (1022.2) micrograms/min to 1072.5 (908.5) micrograms/min (P = NS). Glomerular filtration rates fell from 105.2 (57.5) ml/min per 1.73 m2 to 72.1 (39.4) ml/min per 1.73 m2 in the lisinopril group and from 109.9 (50.0) ml/min per 1.73 m2 to 82.9 (53.9) ml/min per 1.73 m2 in the nifedipine treated group. Renal blood flow fell from 446.8 (217.9) ml/min per 1.73 m2 to 435.1 (243.3) ml/min per 1.73 m2 for the lisinopril group and from 473.0 (216.4) ml/min per 1.73 m2 to 419.0 (278.6) ml/min per 1.73 m2 for the nifedipine group. Differences between the groups were not significant.(ABSTRACT TRUNCATED AT 250 WORDS)

Adolescent↗

Reduced erythropoietin levels as a cause of anaemia in patients with lung cancer.

Measurements of erythropoietin (Ep) levels in patients with the anaemia of chronic disorders due to malignant disease have given variable results. This variation may be due to the wide range of malignancies studied and the assay method (whole animal) used. In this study Ep levels were measured, using the foetal mouse liver assay, in 39 patients with lung cancer and 19 controls. Twelve patients had reduced haemoglobin levels (Hb less than 11.5 g/dl for males and 11 g/dl for females) and the features of the anaemia of chronic disorders. Their mean Ep level was 0.21 iu/ml. This was significantly lower than for the normal controls, whose mean value was 0.31 iu/ml (P less than 0.02). This data supports the concept that lack of an appropriate Ep response to anaemia is one factor in the genesis of anaemia in malignancy.

Anemia↗

Serum ferritin levels in small cell lung cancer.

Serum ferritin levels were measured before treatment, using an immunoradiometric method, in 39 patients with small cell lung cancer. In 11 patients serial estimations were also made. The median serum ferritin level for male patients was 660 micrograms/l (range 13-1329) and for females 306 (range 134-5300), the normal range being 32-501. This increase is significant (P less than 0.001). Serum ferritin levels were not related to metastatic, haematological or iron status. Serial ferritin levels did not reflect the clinical course of the disease. Patients with a pre-treatment serum ferritin of less than 600 micrograms/l had a significant prolongation of median survival compared to those with an initial serum ferritin of greater than 600 micrograms/l (P less than 0.02). Serum ferritin levels are not of value in staging small cell lung cancer nor in monitoring its progress. However, the initial serum ferritin is of prognostic significance.

Adult↗

Specific thromboxane synthetase inhibition and haemostasis in insulin-dependent diabetics.

Specific thromboxane synthetase inhibition is associated with a significant fall in abnormal albumin excretion rate in insulin-dependent diabetics (IDDs). This may be due to an effect on haemostasis or changes in renal blood flow. We have studied the effect of a specific thromboxane synthetase inhibitor, UK-38,485, on coagulation parameters in 15 IDDs, at -8, 0, 8 and 16 weeks after double blind administration of drug or placebo. Serum thromboxane B2 fell in the drug group (695 +/- 205 vs 134 +/- 180 pg/ml, n = 7, p less than 0.001), but not in the placebo group (713 +/- 409 vs 614 +/- 178 pg/ml, n = 8). The drug group showed significant reduction in adrenaline primary maximum (24 +/- 7 vs 37 +/- 7%, p less than 0.05) and ADP maximum (71 +/- 14 vs 81 +/- 7%, p less than 0.05) aggregation not seen in the placebo group. Dilute whole blood clot lysis time was, however, increased in the drug group (7.1 +/- 1.6 vs 6.25 +/- 2.4 hr, p less than 0.05) and no effect was observed in either group on in vivo parameters of platelet aggregation (beta-thromboglobulin, platelet factor 4 and platelet micro-aggregates). We conclude that specific thromboxane synthetase inhibition is probably not associated with an overall improvement in haemostasis and the clinical effects observed cannot be explained on this basis.

Diabetes Mellitus, Type 1↗

Zinc deficiency in senile purpura.

Fasting plasma zinc concentrations were lower in elderly people with senile purpura than in a control group matched for age. No significant difference was found in the mean serum concentration of albumin, which is the main binder of zinc. No other clinical or laboratory findings differentiated the two groups. As the cause of the low plasma zinc values has not been found it is suggested that further studies of the related factors including input, output, and binding should be made before a therapeutic trial is launched.

Aged↗

Effects of dazoxiben on exercise performance in chronic stable angina.

1 We have performed a double-blind, randomized, 7-d cross-over study of the thromboxane synthetase inhibitor dazoxiben (UK 37248) in 20 patients with stable coronary heart disease. 2 All patients had a history of exertional angina of greater than two years duration and no patient had suffered a myocardial infarction in the preceding twelve months. 3 All patients had a positive exercise stress test for myocardial ischaemia and 15 had undergone coronary angiography. All these patients had a 50% narrowing in at least one vessel. 4 All patients were on conventional anti-anginal medication and the doses of their various therapies remained unchanged in the three months prior to and during the study period. 5 Therapy with dazoxiben 200 mg four times daily produced no alteration in the subjective or objective features of angina in these patients. There was no alteration in angina attack rate, glyceryl trinitrate consumption or duration of treadmill exercise. 6 Dazoxiben produced a highly significant reduction in both the resting and the post-exercise levels of serum thromboxane B2 levels, although there was no significant difference between the pre-exercise and post-exercise values. 7 Dazoxiben is an effective inhibitor of the synthesis of thromboxane but it has no effect on the subjective or objective features of stable coronary disease. This would suggest that the production of thromboxane and the development of circulating platelet aggregates play no part in the mechanism of angina in patients with stable coronary heart disease.

Angina Pectoris↗

Haemoglobin concentration and serum erythropoietin in renal dialysis and transplant patients.

In patients with chronic renal failure the use of the relatively new dialysis technique of continuous ambulatory peritoneal dialysis (CAPD), unlike other forms of dialysis, is consistently associated with an increase in Hb concentration, but the mechanism remains obscure. We measured Hb, haematocrit, S-erythropoietin and Hb-oxygen affinity in 3 groups of patients with chronic renal failure. (1) Untreated patients starting on haemodialysis. (2) Patients on intermittent peritoneal dialysis changing to CAPD. (3) Patients from the above 2 groups receiving renal transplants. In addition, red cell mass, plasma volume and red cell survival were measured in (2), before starting CAPD and at 6 months. There were distinctly different patterns of change in Hb concentration, Hb-oxygen affinity and S-erythropoietin in the 3 groups of patients. The increase in Hb concentration with CAPD is due to both a fall in plasma volume and an increase in red cell mass, with an increase in red cell survival. There was no change in Hb-oxygen affinity or serum erythropoietin concentration. The improvement in red cell mass and survival may be related to increased clearances of substances with mol. wt.s between 500 and 5000 daltons which accumulate in renal failure (uraemic middle molecules).

Erythropoietin↗

Association between rising haemoglobin concentration and renal cyst formation in patients on long term regular haemodialysis treatment.

Seventeen of 20 (85%) patients on RDT for six to 13 years were found to have acquired renal cysts. There was a significant positive association between Hb and duration of RDT. The extent of cyst was positively and significantly correlated with the latest Hb and years on dialysis. There was also a significant positive correlation between size and years on dialysis only approached statistical significance. There was no correlation between kidney size and latest Hb. Complications in patients with acquired renal cysts appear to resemble those of familial polycystic disease with the added risk of neoplasia.

Adult↗

The use of topical thrombin to reduce wound haematoma in patients receiving low-dose heparin.

The efficacy of topical thrombin in prevention of wound haematoma in patients receiving subcutaneous low-dose heparin was studied in a randomized, controlled trial. One hundred and two patients undergoing elective abdominal surgery were included in the trial. Haematological studies were carried out in the last 42 patients to determine whether introduction of thrombin into the wound resulted in any systemic effect via the coagulation pathways. The frequency of post-operative wound haematoma was significantly lower in the thrombin-treated group as compared to the control group and its action appeared to be independent of any change in coagulation parameters.

Abdomen↗

Platelet estimation in whole blood.

An application of particle size analysis is described for the estimation of platelet counts in whole blood based on a variable size threshold and baseline. The simplicity of the sample preparation for this technique may enable its automation as a semiquantitative screening method. Platelets, defined as particles to the platelet side and above the minimum point between the platelet and red cell distributions were counted on specially designed electronics. The system divides the normal size distribution from the smallest platelet to the smallest red cell into four equal windows and performs three integrations to calculate the best result. Correlation of results obtained using this technique with results form the sedimentation method produced a coefficient of 0.93. In the trial period of a week in which all the samples (132) normally undergoing platelet count were also counted on the system descirbed, only six false negative results were found, four at the lower end of normal (150000) and two at the upper end (400000). The advantages of an MCA computer-based system are also discussed.

Blood Cell Count↗